DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Investigator: Polly Niravath, MD

Study Coordinator: Kelsey Banaglorioso

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03529110

Phone: 346.238.5740

Protocol Number: Pro00021204


This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
More to Explore